These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Current Development of Glioblastoma Therapeutic Agents. Wang Z; Peet NP; Zhang P; Jiang Y; Rong L Mol Cancer Ther; 2021 Sep; 20(9):1521-1532. PubMed ID: 34172531 [TBL] [Abstract][Full Text] [Related]
49. VEGF-mediated tight junctions pathological fenestration enhances doxorubicin-loaded glycolipid-like nanoparticles traversing BBB for glioblastoma-targeting therapy. Wen L; Tan Y; Dai S; Zhu Y; Meng T; Yang X; Liu Y; Liu X; Yuan H; Hu F Drug Deliv; 2017 Nov; 24(1):1843-1855. PubMed ID: 29182025 [TBL] [Abstract][Full Text] [Related]
50. Lipid-based nanoparticles to address the limitations of GBM therapy by overcoming the blood-brain barrier, targeting glioblastoma stem cells, and counteracting the immunosuppressive tumor microenvironment. Zhao C; Zhu X; Tan J; Mei C; Cai X; Kong F Biomed Pharmacother; 2024 Feb; 171():116113. PubMed ID: 38181717 [TBL] [Abstract][Full Text] [Related]
51. The Application of Ultrasmall Gold Nanoparticles (2 nm) Functionalized with Doxorubicin in Three-Dimensional Normal and Glioblastoma Organoid Models of the Blood-Brain Barrier. Kostka K; Sokolova V; El-Taibany A; Kruse B; Porada D; Wolff N; Prymak O; Seeds MC; Epple M; Atala AJ Molecules; 2024 May; 29(11):. PubMed ID: 38893345 [TBL] [Abstract][Full Text] [Related]
52. High-density lipoprotein-biomimetic nanocarriers for glioblastoma-targeting delivery: the effect of shape. Huang JL; Jiang G; Song QX; Gu X; Song HH; Wang XL; Jiang D; Kang T; Feng XY; Jiang XG; Chen HZ; Gao XL Pharmazie; 2016 Dec; 71(12):709-714. PubMed ID: 29441999 [TBL] [Abstract][Full Text] [Related]
53. Enhancement of Therapies for Glioblastoma (GBM) Using Nanoparticle-based Delivery Systems. Wiwatchaitawee K; Quarterman JC; Geary SM; Salem AK AAPS PharmSciTech; 2021 Feb; 22(2):71. PubMed ID: 33575970 [TBL] [Abstract][Full Text] [Related]
54. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Agarwal S; Sane R; Oberoi R; Ohlfest JR; Elmquist WF Expert Rev Mol Med; 2011 May; 13():e17. PubMed ID: 21676290 [TBL] [Abstract][Full Text] [Related]
55. Advances in nanocarriers enabled brain targeted drug delivery across blood brain barrier. Sharma G; Sharma AR; Lee SS; Bhattacharya M; Nam JS; Chakraborty C Int J Pharm; 2019 Mar; 559():360-372. PubMed ID: 30721725 [TBL] [Abstract][Full Text] [Related]
56. Use of nanoparticles for drug delivery in glioblastoma multiforme. Jain KK Expert Rev Neurother; 2007 Apr; 7(4):363-72. PubMed ID: 17425491 [TBL] [Abstract][Full Text] [Related]
57. Activation of KATP channels increases anticancer drug delivery to brain tumors and survival. Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats T Eur J Pharmacol; 2009 Jan; 602(2-3):188-93. PubMed ID: 19027730 [TBL] [Abstract][Full Text] [Related]
58. Current Challenges and Opportunities in Treating Glioblastoma. Shergalis A; Bankhead A; Luesakul U; Muangsin N; Neamati N Pharmacol Rev; 2018 Jul; 70(3):412-445. PubMed ID: 29669750 [TBL] [Abstract][Full Text] [Related]
59. Drug Repurposing for Glioblastoma and Current Advances in Drug Delivery-A Comprehensive Review of the Literature. Alomari S; Zhang I; Hernandez A; Kraft CY; Raj D; Kedda J; Tyler B Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944514 [TBL] [Abstract][Full Text] [Related]
60. Design of Biopolymer-Based Interstitial Therapies for the Treatment of Glioblastoma. Pena ES; Graham-Gurysh EG; Bachelder EM; Ainslie KM Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884965 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]